NICE (UK) recommends trifluridine–tipiracil combination to treat metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma.-Servier + Taiho Oncology
NICE (UK);Trifluridine–tipiracil (Lonsurf) is recommended, within its marketing authorisation, as an option for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults who have had 2 or more treatment regimens. It is only recommended if the company provides trifluridine–tipiracil according to the commercial arrangement.
Why the committee made these recommendations: This evaluation uses new cost-effectiveness estimates to update trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies (NICE technology appraisal guidance TA669). No new clinical evidence was reviewed.
Standard treatment for metastatic gastric cancer and gastro-oesophageal junction adenocarcinoma, for most people who have had 2 or more treatments, is best supportive care.
The clinical evidence suggests that people having trifluridine–tipiracil live longer compared with best supportive care. When taking into account the severity of the condition and its effect on quality and length of life, the most likely cost-effectiveness estimate is within the range that NICE normally considers an acceptable use of NHS resources. So, trifluridine–tipiracil is recommended.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins